Skip to main content

Table 1 Demographic characteristics (Commercial/Medicare and Medicaid)

From: Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

  Commercial/Medicare Medicaid
  Raloxifene Bisphosphonates Raloxifene Bisphosphonates
  (N = 17,983) (N = 79,891) (N = 11,504) (N = 59,881)
Age (Mean, std.)* 62.2 (9.0) 64.2 (10.7) 69.3 (11.1) 71.8 (10.8)
Age group* % % % %
45–64 69.0 59.8 32.3 23.7
65–74 19.5* 20.2* 34.2* 34.0*
75 and over 11.5 20.0 33.5 42.2
Race *     
White --- --- 33.9 39.9
African American --- --- 5.3 6.2
Hispanic/Latino --- --- 15.1 17.2
Asian --- --- 29.6 21.4
Other --- --- 16.1 15.3
Medicare* 26.6 36.7 --- ---
Location*     
North East 7.3 10.7 --- ---
North Central 34.0 32.9 --- ---
South 46.1 38.5 --- ---
West 12.2 17.7 --- ---
Unknown 0.4 0.3 --- ---
Urban residence* 72.1 78.2 89.4 90.7
Insurance type* 1     
Indemnity 34.5 39.3 82.3 82.3
PPO 44.7 40.8 --- ---
Other 20.8 19.9 17.7 17.7
Provider specialty*     
Specialist2 18.8 16.8 6.5 4.9
  1. *Test for differences between raloxifene and bisphosphonates statistically significant at p < 0.0001
  2. 1 Difference not statistically different (p < 0.05) for Medicaid comparison
  3. 2 Specialist versus primary care or other